Compare Lockheed Martin Corporation (LMT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Lockheed Martin (LMT) trades at $509.59, up 2.08% over the past day, with a bearish technical signal but strong analyst consensus. The company reported mixed quarterly earnings, missing in Q4 2025 and Q1 2026 but beating in Q2 2026, while revenue and cash flow trends show growth. Recent news highlights innovation in AI and autonomous systems, dividend increases, and ongoing defense contracts, supporting a positive long-term outlook despite near-term volatility.

LMT presents a compelling investment case with a consensus price target of $635.33, implying significant upside, backed by robust cash flows and a dominant defense market position. Risks include reliance on government spending, fixed-price contract volatility, and rising debt levels, but the stock's current valuation and dividend track record offer a margin of safety for patient investors.

Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.

The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.